ReviewBMC pediatrics2025
Insulin autoimmune syndrome in a 3-year-old boy: the youngest to date in China and a narrow review.
Review in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Alpha-lipoic acid as a trigger of insulin autoimmune syndrome: Current evidence, a case-based approach, diagnostic pitfalls, and practical management.Metabolism open · 2026Review
- Averting Potential Misinterpretations and Diagnostic Misapplications of Misleading Laboratory Results.Diagnostics (Basel, Switzerland) · 2026Review
- Diagnostic utility of the insulin-to-C-peptide molar ratio in differentiating insulin autoimmune syndrome and exogenous insulin antibody syndrome from insulinoma.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundInsulin autoimmune syndrome (IAS), characterized by endogenous hypoglycemia associated with insulin autoantibodies, is a rare cause of hypoglycemia in pediatric patients. Here, we report a case of the youngest patient with IAS in China, and summarize the clinical characteristics of the disease through a narrow review of pediatric cases. CASE PRESENTATION: A 3-year-10-month-old Chinese boy presented with unconsciousness. Initially, he was misdiagnosed with hyperinsulinemic hypoglycemia (HH) due to non-ketotic hypoglycemia. Whole exome sequencing (WES) was negative, and no pancreatic space-occupying lesions were identified. He continued to have intermittent episodes of symptomatic hypoglycemia. During an extended oral glucose tolerance test (OGTT), his insulin to C-peptide molar ratio was greater than 1, and anti-insulin antibodies (IAAs) measurements were as high as 54.38 COI (normal range 0-1 COI). High-resolution human leukocyte antigen (HLA) test showed a DRB1*08:03/*12:02 genotype. He was eventually diagnosed with IAS. Hypoglycemic episodes were not observed as long as the patient adhered to the low and frequent carbohydrate diet. Six months later, the patient's anti-insulin antibody had decreased to 10.17 COI, and mildly symptomatic hypoglycemia occasionally occurred in the case of noncompliance with the diet. Based on 11 studies from a literature review and our own case, a total of 12 pediatric patients were analyzed. Most of these patients presented with unconsciousness initially and their episodes of hypoglycemia do not follow a definitive pattern. Adjustments in diet serve as an effective intervention, and spontaneous remission is relatively common.
conclusionWhen differentiating the causes of HH in pediatric patients, IAS should not be overlooked. Elevated levels of IAAs and an inappropriate insulin to C-peptide molar ratio during an extended OGTT are critical indicators. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.